But you cannot do that by your own policy.

So you are saying that you ratify them after they have been paid for?

The Committee looks forward to receiving the VA's detailed plan on changes to its acquisition structure for prosthetics.

Let me ask it one more time. When?

I think we have a better understanding of where you are coming from, but I think you also have a better understanding of our concerns as well.

Actions by the VA's purchasing agents have greatly reduced the chances for getting the best value in prosthetics acquisition.

However, it is also clear that actions by the VA's purchasing agents have greatly reduced the chances for getting the best value in prosthetics acquisition.

Will the VA be able to effectively recover money that it overpaid to vendors?

Could you briefly explain some of the criteria that the Association of Tissue Banks, AATB, has to ensure patient safety?

In March of this year, I sent a letter to the Secretary regarding the VA's procurement of biologics over the open market instead of from better-known small businesses already on the Federal supply schedule.

Does the Department of Defense use any mechanism similar to section 8123 of title 38 for its acquisition of prosthetic appliances?

Okay, how do the various biologics manufacturers work cohesively together? Do they commingle?

You note the VA's new policy for purchases over $3,000.

I request your response to the enclosed questions for the record I am submitting in reference to the Oversight and Investigations Subcommittee hearing entitled 'Purchasing Perspective: VA's Prosthetics Paradox.'

Are there any instances where DoD doesn't document procurements, whether they are on- or off-contract?

Such an inclusive definition means that small policy changes can have impacts on areas that would not otherwise be impacted.

You won't run a business that way.

You know, not doing things for 30 years, working off of expired directives, 11 years between reviewing documents. That is part of what has gotten us into this mess now, wouldn't you agree?

We call on this Subcommittee to seriously consider passage of H.R. 805, the Injured and Amputee Veterans Bill of Rights.

Chairman Johnson, thank you for the opportunity to discuss our work.

Where do biologics manufacturers procure their donors?

Do you think overpayments will cease in the near future?

How can a surgeon or VA facility be assured that the biologics they purchase are indeed safe for the patient?

Let me re-ask my question because it sounds like you are saying that you have already gone into the execution phase of the plan.

The VA's sweeping definition for prosthetics opens the door for confusion.